MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Chorea (also see specific diagnoses, Huntingtons disease, etc): Treatment"

  • 2023 International Congress

    Effectiveness of deep brain stimulation in the treatment of Huntington’s disease

    H. Rodrigues, G. Mantovani, M. da Rosa, V. de Souza, L. Aires, M. Fin, L. Lobato, R. Albuquerque, PL. da Silva, A. Hilbig (Porto Alegre, Brazil)

    Objective: The aim is to obtain relevant information regarding the effectiveness of using Deep Brain Stimulation (DBS) as a treatment of Huntington's disease (HD). Background:…
  • 2023 International Congress

    Crushing valbenazine capsule contents for potential addition to soft foods or administration via G tube

    M. Hebert, A. Mar, R. Moore, A. Bristow, S. Siegert (San Diego, USA)

    Objective: To evaluate the suitability of mixing crushed contents from valbenazine capsules with soft foods/liquids or adding them to water for delivery through a gastrostomy…
  • 2023 International Congress

    Chorea improvements over time with once-daily valbenazine treatment in adults with Huntington disease

    E. Furr Stimming, E. Kayson, J. Goldstein, H. Zhang, O. Klepitskaya, G. Liang, D. Haubenberger (Houston, USA)

    Objective: To describe the effects of valbenazine (VBZ) over time on chorea in adults with Huntington disease (HD). Background: The Ph3 KINECTTM-HD (NCT04102579) trial met…
  • 2023 International Congress

    Melatonin for huntington disease (HD) gene carriers with HD-related sleep disturbance – a pilot study

    J. Patino, S. Zadegan, N. Rocha, N. Karagas, W. Tanigaki, B. Duncan, E. Furr Stimming (Houston, USA)

    Objective: To evaluate the efficacy of exogenous melatonin in improving sleep quality in Huntington disease (HD) gene carriers. Background: Various sleep disorders have been identified…
  • 2023 International Congress

    A minimal clinically important difference for UHDRS® Total Maximal Chorea score as a measure of chorea severity in Huntington disease

    E. Furr Stimming, D. Claassen, E. Kayson, J. Goldstein, H. Zhang, O. Klepitskaya, G. Liang, D. Haubenberger (Houston, USA)

    Objective: To establish a minimal clinically important difference (MCID) for the Unified Huntington Disease Rating Scale (UHDRS®) Total Maximal Chorea (TMC) score as a measure…
  • 2023 International Congress

    Metoclopramide-induced acute dystonic reaction caused by CYP2D6 *4/*4 and CYP2D6 *10/*10 genotypes

    I. šarac, H. šarac, F. Borovečki, N. Božina, I. Ivek, L. Bagarić Krakan, Z. Krešić (Zagreb, Croatia)

    Objective: Objective is to demonstrated the role of CYP P450 2D6 polymorphisms in metoclopramide-induced acute dystonic reactions. Background: Metoclopramide can induce acute extrapyramidal reactions by…
  • 2023 International Congress

    Deep brain stimulation in chorea: four cases and literature review

    M. Hull, M. Parnes, A. Tarakad (Houston, USA)

    Objective: We present four cases of pediatric chorea managed with deep brain stimulation (DBS) and review previously reported cases in the literature. We review clinical…
  • 2023 International Congress

    Indirect treatment comparison of valbenazine with deutetrabenazine for improvement in total maximal chorea score in Huntington disease

    R. Mehanna, E. Furr Stimming, D. Haubenberger, O. Klepitskaya, S. Aggarwal, S. Kumar, O. Topaloglu, J. Goldstein, E. Kayson, M. Serbin (Houston, USA)

    Objective: To conduct an indirect treatment comparison (ITC) between valbenazine and deutetrabenazine using data from clinical trials in adults with chorea associated with Huntington disease…
  • 2023 International Congress

    Modifying clinical and electrophysiological parameters through Transcranial pulsed current stimulation (tPCS) in Huntington disease

    M. Tuesta Bernaola, J. Ganguly, A. Parra Peña, M. Jog (London, Canada)

    Objective: 1. To assess brain network dysfunction of Huntington disease (HD). 2. To evaluate the effectiveness of 2-week home-based chronic non-invasive transcranial brain stimulation to…
  • 2022 International Congress

    Real-World Treatment Patterns and Outcomes in Patients With Chorea Associated With Huntington Disease Using Tetrabenazine or Deutetrabenazine in Combination with Antipsychotic Drugs

    D. Claassen, H. Romdhani, R. Ayyagari, D. Goldschmidt, S. Zoye Moroz, A. Hernandez, S. Leo (Nashville, USA)

    Objective: To describe treatment patterns with vesicular monoamine transporter 2 inhibitors (VMAT2i; tetrabenazine [TBZ], or deutetrabenazine [DTBZ]) in combination with antipsychotic agents (APs) in patients…
  • « Previous Page
  • 1
  • …
  • 4
  • 5
  • 6
  • 7
  • 8
  • …
  • 12
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley